°Õ±ð³§¸éâ„¢ Feeder-Free Pluripotent Stem Cell (PSC) Culture Media
°Õ±ð³§¸éâ„¢ Pluripotent Stem Cell Culture Media
Feeder-Free Media for Human ES and iPS Cell Reprogramming, Maintenance, and Differentiation
The TeSR™ family of feeder-free media are produced using rigorously pre-screened materials to ensure the highest levels of batch-to-batch consistency and experimental reproducibility, allowing you to minimize variation in your research. Each medium is based on published formulations1-3 from the laboratory of James Thomson, and allows researchers to maintain high quality human pluripotent stem cell (hPSC) culture systems. These products provide a continuous TeSR™ media-based workflow, from generation of induced pluripotent stem (iPS) cells, to maintenance, differentiation and cryopreservation of embryonic stem (ES) and iPS cells.
Why Use mTeSR™ and the TeSR™ Media Family?
- Feeder-free hPSC culture minimizes variability by limiting the presence of undefined components and immunogenic material.
- m°Õ±ð³§¸éâ„¢ is the most widely published medium for hPSC culture with > 1500 peer-reviewed publications.
- The same base formulation in each medium allows for establishment of a continuous TeSR™ media-based workflow.
Choose Your °Õ±ð³§¸éâ„¢ Maintenance Medium
Use the Interactive Product Finder or this infographic to choose the °Õ±ð³§¸éâ„¢ hPSC culture medium that is best suited for your needs.
e°Õ±ð³§¸éâ„¢
Formulation:
Serum-Free
Applications:
Feeder-free maintenance and expansion of human ES and iPS cells, optimized for single-cell passaging.
Features/Advantages:
- Enhanced buffering, stabilization of FGF2, and optimized metabolites support cell quality while allowing for alternative feeding schedules
- Improves the genetic stability of hPSC cultures when performing routine single-cell passaging
- Increases cell yields while reducing the stress associated with single-cell passaging or high-density cultures
- Eliminates spontaneous differentiation
m°Õ±ð³§¸éâ„¢ Plus
Formulation:
Serum-Free
Applications:
Feeder-free maintenance and expansion of human ES and iPS cells.
Features/Advantages:
- Enhanced buffering and stabilized FGF2 support cell quality while allowing for alternate feeding schedules
- Supports superior culture morphology and cell growth characteristics
- Enables heightened single-cell survival when used with CloneRâ„¢
- Fully compatible with established genome editing and differentiation protocols
- Manufactured under relevant cGMPs, enabling a seamless transition from fundamental research to drug and cell therapy development.
°Õ±ð³§¸éâ„¢-AOF
Formulation:
Serum-Free, Animal Origin-Free
Applications:
Feeder-free maintenance and expansion of human ES and iPS cells.
Features/Advantages:
- De-risk your choice of ancillary materials by selecting a medium with no animal raw materials to the secondary level of manufacturing
- Supports high-quality colony morphology, robust attachment, and cell expansion
- Stabilized components, including FGF2, support high cell quality while allowing for alternate feeding schedules
m°Õ±ð³§¸éâ„¢1
Formulation:
Serum-Free
Applications:
Feeder-free maintenance and expansion of human ES and iPS cells.
Features/Advantages:
- Used to maintain thousands of human ES and iPS cell lines in over 60 countries for 10 years
- Contains pre-screened BSA to stabilize medium, aid in lipid/nutrient transport, and protect cultures from cellular toxins and stresses
- Maintenance medium of choice for many published protocols for lineage-specific differentiation of hPSCs
m°Õ±ð³§¸éâ„¢1 Without Phenol Red
Formulation:
Serum-Free
Applications:
Feeder-free maintenance and expansion of human ES and iPS cells.
Features/Advantages:
- Used to maintain thousands of human ES and iPS cell lines in over 60 countries for 10 years
- Contains pre-screened BSA to stabilize medium, aid in lipid/nutrient transport, and protect cultures from cellular toxins and stresses
- Maintenance medium of choice for many published protocols for lineage-specific differentiation of hPSCs
°Õ±ð³§¸éâ„¢-E8â„¢
Formulation:
Animal Component-Free; Serum-Free
Applications:
Feeder-free maintenance and expansion of human ES and iPS cells.
Features/Advantages:
- Cutting-edge, animal component-free formulation
- Contains only the 8 most critical components required for hPSC maintenance
RSeTâ„¢ Feeder-Free Medium
Formulation:
Serum-Free
Applications:
Reversion of primed human ES and iPS cells to a naïve-like state and their maintenance in a naïve-like state under hypoxic conditions.
Features/Advantages:
- Feeder-independent culture system reduces inherent variability, cost, and burden of feeder preparation
- Serum-free formulation contains pre-screened quality components for reproducible results
- Facilitates highly efficient reversion to naïve-like state with stable domed morphology, naïve gene expression profiles, and low levels of spontaneous differentiation without the need for exogenous genes
- Maintains naïve-like pluripotency without inclusion of bFGF
Collapse Details
cGMP hPSC Maintenance Medium
Think forward to the clinic in your hPSC research. Our stabilized feeder-free hPSC maintenance medium, m°Õ±ð³§¸éâ„¢ Plus, is now manufactured and tested following relevant cGMPs under a certified quality management system. Find more information about regulatory compliance at º£½ÇÆƽâ°æ >
How is m°Õ±ð³§¸éâ„¢ Plus different from other maintenance media?
m°Õ±ð³§¸éâ„¢ Plus was designed based on the formulation of m°Õ±ð³§¸éâ„¢1. This version contains stabilized components including FGF2 and unlike other media offers enhanced buffering to reduce medium acidification so that cell quality is preserved during skipped media changes.
Advantages:
- Enhanced buffering and stabilized FGF2 support cell quality while allowing for alternate feeding schedules
- Supports superior culture morphology and cell growth characteristics
- Enables heightened single-cell survival when used with CloneRâ„¢
- Fully compatible with established genome editing and differentiation protocols
- Manufactured under relevant cGMPs, enabling a seamless transition from fundamental research to drug and cell therapy development
Learn more about m°Õ±ð³§¸éâ„¢ Plus and try it in your own lab.
°Õ±ð³§¸éâ„¢-E5
Formulation:
Serum-Free; Xeno-Free
Applications:
Differentiation of human ES and iPS cells.
Features/Advantages:
- Based on °Õ±ð³§¸éâ„¢-E8â„¢, but does not contain bFGF, °Õ³Ò¹óβ, or insulin
- Ideal for differentiation to lineages, such as cardiomyocyte, in which insulin is a known inhibitor
°Õ±ð³§¸éâ„¢-E6
Formulation:
Serum-Free; Xeno-Free
Applications:
Differentiation of human ES and iPS cells.
Features/Advantages:
- Based on °Õ±ð³§¸éâ„¢-E8â„¢, but does not contain bFGF or °Õ³Ò¹óβ
- Lineage-neutral base formulation ideal for differentiation, screening, and other applications
Collapse Details
Consistent differentiation of ES and iPS cell lines can be challenging. We recommend our ³§°Õ·¡²Ñ»å¾±´Ú´Úâ„¢ suite of products for optimal and reproducible differentiation.
CryoStor® CS10
Formulation:
cGMP-Manufactured; Animal Component-Free; Serum-Free
Applications:
Cryopreservation of human ES and iPS cells.
Features/Advantages:
- Animal component-free
- Maintains high cell viability and maximizes cell recovery after long-term storage
³¾¹ó°ù±ð³§¸éâ„¢
Formulation:
Serum-Free
Applications:
Cryopreservation of human ES and iPS cells.
Features/Advantages:
- Optimized for hPSCs preserved as aggregates
- Higher thawing efficiencies than reported with conventional serum-containing media
¹ó°ù±ð³§¸éâ„¢-³§
Formulation:
Animal Component-Free; Serum-Free
Applications:
Cryopreservation of human ES and iPS cells as single cells.
Features/Advantages:
- Animal component-free
- Optimized for cryopreservation of cells in single-cell suspension
- Higher thawing efficiencies than reported with conventional serum-containing media
Collapse Details
Repro°Õ±ð³§¸éâ„¢ Medium for Reprogramming
Formulation:
Serum-Free; Xeno-Free
Applications:
Generation of human iPS cells from fibroblasts, urine-derived cells, and blood-derived cells such as CD34+ or erythroid precursor cells.
Features/Advantages:
- Defined, feeder-free formulation facilitates reproducibly efficient human iPS cell generation
- Rapid emergence of large colonies with high-quality iPS cell-like morphology facilitates identification and subcloning for easily establishing iPS cell lines
- Seamlessly integrates with º£½ÇÆƽâ°æ products prior to reprogramming and after iPS cell generation for maintenance and differentiation
°Õ±ð³§¸éâ„¢-E7â„¢ Medium for Reprogramming
Formulation:
Serum-Free; Xeno-Free; Animal Component-Free
Applications:
Generation of human iPS cells without the use of feeders.
Features/Advantages:
- Pre-screened components ensure high quality iPS cell colony morphology for easy identification and improved manual selection
- Reduced differentiation and fibroblast growth enables rapid establishment of homogeneous iPS cell cultures
- Feeder-free, defined formulation facilitates reproducibly efficient human iPS cell generation
Erythroid Progenitor Reprogramming Kit
Formulation:
Animal Component-Free; Serum-Free
Applications:
Isolation and expansion of erythroid progenitor cells from peripheral blood and their subsequent reprogramming to iPS cells.
Features/Advantages:
- Optimized for enrichment, expansion and reprogramming of erythroid progenitor cells expanded from peripheral blood samples
- Improved reprogramming efficiency and higher frequency of iPS cell colonies, compared to traditional hES cell medium
- Rapid emergence of large colonies with high quality iPS cell-like morphology facilitates identification and subcloning
- Seamlessly integrates with °Õ±ð³§¸éâ„¢ and ³§°Õ·¡²Ñ»å¾±´Ú´Úâ„¢ products for downstream maintenance and differentiation of iPS cell lines
CD34+ Progenitor Reprogramming Kit
Formulation:
Serum-Free
Applications:
Isolation and expansion of CD34+ progenitor cells from peripheral blood and their subsequent reprogramming to iPS cells.
Features/Advantages:
- Optimized for enrichment, expansion and reprogramming of CD34+ progenitor cells expanded from peripheral blood samples
- Improved reprogramming efficiency and higher frequency of iPS cell colonies, compared to traditional hES cell medium
- Rapid emergence of large colonies with high quality iPS cell-like morphology facilitates identification and subcloning
- Seamlessly integrates with °Õ±ð³§¸éâ„¢ and ³§°Õ·¡²Ñ»å¾±´Ú´Úâ„¢ products for downstream maintenance and differentiation of iPS cell lines
¸é±ð±è°ù´Ç¸é±·´¡â„¢-°¿°³§³Ò²Ñ
Applications:
Reprogramming of somatic cells, such as fibroblasts, into iPS cells.
Features/Advantages:
- Non-viral, non-integrating vector system
- Self-replicating vector only requires a single transfection
- Vector contains all reprogramming factors
- Comparable fibroblast reprogramming efficiency to Sendai virus
Collapse Details
m°Õ±ð³§¸éâ„¢3D
Formulation:
Serum-Free
Applications:
Expansion and scale-up of undifferentiated human ES and iPS cells as aggregates in 3D suspension culture.
Features/Advantages:
- Based on m°Õ±ð³§¸éâ„¢1, optimized formulation for hPSC scale-up
- Fed-batch culture system for a simplified workflow
- Scale up to 109 high-quality, undifferentiated hPSCs in as few as 2 - 3 weeks
°Õ±ð³§¸éâ„¢-E8â„¢3D
Formulation:
Animal Component-Free
Applications:
Expansion and scale-up of undifferentiated human ES and iPS cells as aggregates in 3D suspension culture.
Features/Advantages:
- Based on °Õ±ð³§¸éâ„¢-E8â„¢, optimized for hPSC scale-up in low protein, animal component-free conditions
- Fed-batch culture system for a simplified workflow
- Scale up to 109 high-quality, undifferentiated hPSCs in as few as 2 - 3 weeks
°Õ±ð³§¸éâ„¢-AOF 3D
Formulation:
Animal Origin-Free
Applications:
Expansion and scale-up of undifferentiated human ES and iPS cells as aggregates in 3D suspension culture.
Features/Advantages:
- Based on °Õ±ð³§¸éâ„¢-AOF, optimized for hPSC scale-up with no animal raw materials to the secondary level of manufacturing
- Fed-batch culture system for a simplified workflow
- Scale up to 109 high-quality, undifferentiated hPSCs in as few as 2 - 3 weeks
Collapse Details
What Are the Functions of Cytokines in TeSR™ Media and Their Impact on hPSC Culture?
- promotes cell survival and proliferation, while also inhibiting differentiation to specific lineages (e.g. cardiomyocytes). It is present in all of our TeSR™ media (except for TeSR™-E5).
- is an important cytokine for hPSC self-renewal and expansion and can be found in the TeSR™ reprogramming (ReproTeSR™, TeSR™-E7™) and maintenance (, , ) media.
- inhibits reprogramming and is important for maintenance of hPSC pluripotency. °Õ³Ò¹óβ is found in all three TeSR™ maintenance media (, , ).
Brand History
In 2006, Dr. Tenneille Ludwig and colleagues of Dr. James Thomson’s lab at the University of Wisconsin reported the derivation of a new ES cell line in fully defined, feeder-free culture conditions.1,2 This first defined medium significantly improved human ES cell culture, and was commercially released as m°Õ±ð³§¸éâ„¢1, becoming the most widely published feeder-free medium, used in over 1100 peer-reviewed publications. Later, a xeno-free medium based on the same formulation was released as °Õ±ð³§¸éâ„¢2. In 2012, a new, low-protein maintenance medium called °Õ±ð³§¸éâ„¢-E8â„¢ was released. Based on the E8 formulation3 published by Dr. Guokai Chen of Dr. James Thomson’s lab, °Õ±ð³§¸éâ„¢-E8â„¢ contains only the most essential media components required, thereby providing a simpler medium for maintenance of hPSCs.
More recently, m°Õ±ð³§¸éâ„¢ Plus (2019) and °Õ±ð³§¸éâ„¢-AOF (Animal Origin-Free; 2021) have been released as part of º£½ÇÆƽâ°æ Technologies' °Õ±ð³§¸éâ„¢ product line. m°Õ±ð³§¸éâ„¢-Plus, a feeder-free maintenance medium, allows for weekend-free schedules and differs from m°Õ±ð³§¸éâ„¢1 in its enhanced pH buffering. °Õ±ð³§¸éâ„¢-AOF is guaranteed to be free of human and animal materials to the secondary level of manufacturing, providing users with peace-of-mind around viral safety. m°Õ±ð³§¸éâ„¢ Plus, °Õ±ð³§¸éâ„¢-AOF, and m°Õ±ð³§¸éâ„¢1 are all manufactured under relevant cGMPs.
In addition to °Õ±ð³§¸éâ„¢ maintenance media, º£½ÇÆƽâ°æ Technologies has developed °Õ±ð³§¸éâ„¢-based media to support other facets of the pluripotent stem cell research workflow, including media optimized for reprogramming fibroblasts (°Õ±ð³§¸éâ„¢-E7â„¢), reprogramming blood cells and fibroblasts (Repro°Õ±ð³§¸éâ„¢), differentiation (°Õ±ð³§¸éâ„¢-E6 and °Õ±ð³§¸éâ„¢-E5), and cryopreservation (³¾¹ó°ù±ð³§¸éâ„¢ and ¹ó°ù±ð³§¸éâ„¢-³§).
Scientific Resources
Quality Control for Pluripotent Stem Cells
Get to know the key quality attributes of hPSC cultures, including techniques for maintaining and assessing genomic integrity, pluripotency, and morphology.
Panel: Challenges in Ensuring hPSC Quality
Hear global experts discuss key issues impacting the use of human pluripotent stem cells in this series of webinars provided in partnership with Nature Research.
Explore more helpful resources for your hPSC research in our pluripotent resource centers and cell culture methods library
Key Applications
Toxicity Testing with Human iPS Cells
Jagtap S, Meganathan K, Gaspar J, Wagh V, Winkler J, Hescheler J and Sachinidis A (2011), , Br J Pharmacol. Vol. 162, pp. 1743-56.
Kleinstreuer NC, Smith AM, West PR, Conard KR, Fontaine BR, Weir-Hauptman AM, Palmer JA, Knudsen TB, Dix DJ, Donley ELR and Cezar GG (2011), , Toxicology and Applied Pharmacology., November, 2011. Vol. 257(1), pp. 111-121.
Liang P, Lan F, Lee AS, Gong T, Sanchez-Freire V, Wang Y, Diecke S, Sallam K, Knowles JW, Wang PJ, Nguyen PK, Bers DM, Robbins RC and Wu JC (2013), Circulation., April, 2013. Vol. 127(16), pp. 1677-1691.
Liu J, Sun N, Bruce MA, Wu JC and Butte MJ (2012), , PLoS ONE., May, 2012. Vol. 7(5), pp. e37559.
Mehta A, Chung YY, Ng A, Iskandar F, Atan S, Wei H, Dusting G, Sun W, Wong P and Shim W (2011), , Cardiovascular Research., September, 2011. Vol. 91(4), pp. 577-586.
Kleinstreuer NC, Smith AM, West PR, Conard KR, Fontaine BR, Weir-Hauptman AM, Palmer JA, Knudsen TB, Dix DJ, Donley ELR and Cezar GG (2011), , Toxicology and Applied Pharmacology., November, 2011. Vol. 257(1), pp. 111-121.
Liang P, Lan F, Lee AS, Gong T, Sanchez-Freire V, Wang Y, Diecke S, Sallam K, Knowles JW, Wang PJ, Nguyen PK, Bers DM, Robbins RC and Wu JC (2013), Circulation., April, 2013. Vol. 127(16), pp. 1677-1691.
Liu J, Sun N, Bruce MA, Wu JC and Butte MJ (2012), , PLoS ONE., May, 2012. Vol. 7(5), pp. e37559.
Mehta A, Chung YY, Ng A, Iskandar F, Atan S, Wei H, Dusting G, Sun W, Wong P and Shim W (2011), , Cardiovascular Research., September, 2011. Vol. 91(4), pp. 577-586.
Differentiating to Hematopoietic Cells
Brown ME, Rondon E, Rajesh D, Mack A, Lewis R, Feng X, Zitur LJ, Learish RD and Nuwaysir EF (2010), , PLoS One. Vol. 5, pp. e11373.
Carpenter L, Malladi R, Yang C-T, French A, Pilkington KJ, Forsey RW, Sloane-Stanley J, Silk KM, Davies TJ, Fairchild PJ, Enver T and Watt SM (2011), , Blood., April, 2011. Vol. 117(15), pp. 4008-4011.
Dravid G, Zhu Y, Scholes J, Evseenko D and Crooks GM (2011), , Mol Ther. Vol. 19, pp. 768-81.
Niwa A, Heike T, Umeda K, Oshima K, Kato I, Sakai H, Suemori H, Nakahata T and Saito MK (2011), , PLoS One. Vol. 6, pp. e22261.
Salvagiotto G, Burton S, Daigh CA, Rajesh D, Slukvin II and Seay NJ (2011), , PLoS ONE., March, 2011. Vol. 6(3), pp. e17829.
Carpenter L, Malladi R, Yang C-T, French A, Pilkington KJ, Forsey RW, Sloane-Stanley J, Silk KM, Davies TJ, Fairchild PJ, Enver T and Watt SM (2011), , Blood., April, 2011. Vol. 117(15), pp. 4008-4011.
Dravid G, Zhu Y, Scholes J, Evseenko D and Crooks GM (2011), , Mol Ther. Vol. 19, pp. 768-81.
Niwa A, Heike T, Umeda K, Oshima K, Kato I, Sakai H, Suemori H, Nakahata T and Saito MK (2011), , PLoS One. Vol. 6, pp. e22261.
Salvagiotto G, Burton S, Daigh CA, Rajesh D, Slukvin II and Seay NJ (2011), , PLoS ONE., March, 2011. Vol. 6(3), pp. e17829.
Differentiating to Definitive Endoderm
Hannoun Z, Fletcher J, Greenhough S, Medine C, Samuel K, Sharma R, Pryde A, Black JR, Ross JA, Wilmut I, Iredale JP and Hay DC (2010), , Cell Reprogram. Vol. 12, pp. 133-40.
Jaramillo M and Banerjee I (2012), , Journal of Visualized Experiments., March, 2012. (61)
Miki T, Ring A and Gerlach J (2011), , Tissue Eng Part C Methods. Vol. 17, pp. 557-68.
Mou H, Zhao R, Sherwood R, Ahfeldt T, Lapey A, Wain J, Sicilian L, Izvolsky K, Lau FH, Musunuru K, Cowan C and Rajagopal J (2012), , Cell Stem Cell., April, 2012. Vol. 10(4), pp. 385-397.
Spence JR, Mayhew CN, Rankin SA, Kuhar MF, Vallance JE, Tolle K, Hoskins EE, Kalinichenko VV, Wells SI, Zorn AM, Shroyer NF and Wells JM (2011), , Nature., February, 2011. Vol. 470(7332), pp. 105-109.
Jaramillo M and Banerjee I (2012), , Journal of Visualized Experiments., March, 2012. (61)
Miki T, Ring A and Gerlach J (2011), , Tissue Eng Part C Methods. Vol. 17, pp. 557-68.
Mou H, Zhao R, Sherwood R, Ahfeldt T, Lapey A, Wain J, Sicilian L, Izvolsky K, Lau FH, Musunuru K, Cowan C and Rajagopal J (2012), , Cell Stem Cell., April, 2012. Vol. 10(4), pp. 385-397.
Spence JR, Mayhew CN, Rankin SA, Kuhar MF, Vallance JE, Tolle K, Hoskins EE, Kalinichenko VV, Wells SI, Zorn AM, Shroyer NF and Wells JM (2011), , Nature., February, 2011. Vol. 470(7332), pp. 105-109.
Scale-Up and Bioreactor Culture
Krawetz R, Taiani JT, Liu S, Meng G, Li X, Kallos MS and Rancourt DE (2010), , Tissue Engineering Part C: Methods., August, 2010. Vol. 16(4), pp. 573-582.
Oh SKW, Chen AK, Mok Y, Chen X, Lim U-M, Chin A, Choo ABH and Reuveny S (2009), , Stem Cell Research., May, 2009. Vol. 2(3), pp. 219-230.
Olmer R, Haase A, Merkert S, Cui W, Palecek J, Ran C, Kirschning A, Scheper T, Glage S, Miller K, Curnow EC, Hayes ES and Martin U (2010), , Stem Cell Res. Vol. 5, pp. 51-64.
Singh H, Mok P, Balakrishnan T, Rahmat SN and Zweigerdt R (2010), , Stem Cell Res. Vol. 4, pp. 165-79.
Zweigerdt R, Olmer R, Singh H, Haverich A and Martin U (2011), , Nature Protocols. Vol. 6(5), pp. 689-700.
Oh SKW, Chen AK, Mok Y, Chen X, Lim U-M, Chin A, Choo ABH and Reuveny S (2009), , Stem Cell Research., May, 2009. Vol. 2(3), pp. 219-230.
Olmer R, Haase A, Merkert S, Cui W, Palecek J, Ran C, Kirschning A, Scheper T, Glage S, Miller K, Curnow EC, Hayes ES and Martin U (2010), , Stem Cell Res. Vol. 5, pp. 51-64.
Singh H, Mok P, Balakrishnan T, Rahmat SN and Zweigerdt R (2010), , Stem Cell Res. Vol. 4, pp. 165-79.
Zweigerdt R, Olmer R, Singh H, Haverich A and Martin U (2011), , Nature Protocols. Vol. 6(5), pp. 689-700.
Differentiating to Cardiomyocytes
Elliott DA, Braam SR, Koutsis K, Ng ES, Jenny R, Lagerqvist EL, Biben C, Hatzistavrou T, Hirst CE, Yu QC, Skelton RJ, Ward-van Oostwaard D, Lim SM, Khammy O, Li X, Hawes SM, Davis RP, Goulburn AL, Passier R, Prall OW, Haynes JM, Pouton CW, Kaye DM, Mummery CL, Elefanty AG and Stanley EG (2011), , Nat Methods. Vol. 8, pp. 1037-40.
Hazeltine LB, Simmons CS, Salick MR, Lian X, Badur MG, Han W, Delgado SM, Wakatsuki T, Crone WC, Pruitt BL and Palecek SP (2012), , International Journal of Cell Biology. Vol. 2012, pp. 1-13.
Lian X, Hsiao C, Wilson G, Zhu K, Hazeltine LB, Azarin SM, Raval KK, Zhang J, Kamp TJ and Palecek SP (2012), , Proceedings of the National Academy of Sciences., July, 2012. Vol. 109(27), pp. 10759-10760.
Mehta A, Chung YY, Ng A, Iskandar F, Atan S, Wei H, Dusting G, Sun W, Wong P and Shim W (2011), , Cardiovascular Research., September, 2011. Vol. 91(4), pp. 577-586.
Zhang H, Zou B, Yu H, Moretti A, Wang X, Yan W, Babcock JJ, Bellin M, McManus OB, Tomaselli G, Nan F, Laugwitz K-L and Li M (2012), , Proceedings of the National Academy of Sciences., July, 2012. Vol. 109(29), pp. 11866-11871.
Hazeltine LB, Simmons CS, Salick MR, Lian X, Badur MG, Han W, Delgado SM, Wakatsuki T, Crone WC, Pruitt BL and Palecek SP (2012), , International Journal of Cell Biology. Vol. 2012, pp. 1-13.
Lian X, Hsiao C, Wilson G, Zhu K, Hazeltine LB, Azarin SM, Raval KK, Zhang J, Kamp TJ and Palecek SP (2012), , Proceedings of the National Academy of Sciences., July, 2012. Vol. 109(27), pp. 10759-10760.
Mehta A, Chung YY, Ng A, Iskandar F, Atan S, Wei H, Dusting G, Sun W, Wong P and Shim W (2011), , Cardiovascular Research., September, 2011. Vol. 91(4), pp. 577-586.
Zhang H, Zou B, Yu H, Moretti A, Wang X, Yan W, Babcock JJ, Bellin M, McManus OB, Tomaselli G, Nan F, Laugwitz K-L and Li M (2012), , Proceedings of the National Academy of Sciences., July, 2012. Vol. 109(29), pp. 11866-11871.
References
- Ludwig TE et al. (2006) Feeder-independent culture of human embryonic stem cells. Nat Methods 3(8): 637–46.
- Ludwig TE et al. (2006) Derivation of human embryonic stem cells in defined conditions. Nat Biotechnol 24(2): 185–7.
- Chen G et al. (2011) Chemically defined conditions for human iPSC derivation and culture. Nat Methods 8(5): 424–9.
